Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
Results
..
All voxvoganan studies
..
Meta analysis
..
Feedback
Home
←
next
study
→
previous
study
c19early.org COVID-19 treatment researchVoxvogananVoxvoganan (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis
 

A Double-blind, Placebo-controlled, Interventional Parallel Group Study to Evaluate the Antiviral Effect of a Single Nasal Application of LTX-109 3% Gel, in Comparison to Placebo Gel, in Subjects With COVID-19 Infection.

Lütken et al., NCT04854928, NCT04854928, May 2022
Source
PDF
All
Studies
Meta
Analysis
https://c19early.org/lutken.html
Viral load, combined -29% improvement lower risk ← → higher risk Viral load, deep nasal.. 6% Viral load, anterior na.. -93% Voxvoganan  Lütken et al.  EARLY TREATMENT RCT Is early treatment with voxvoganan beneficial for COVID-19? Double-blind RCT 33 patients in Sweden No significant difference in viral clearance c19early.org Lütken et al., NCT04854928, May 2022 0 0.5 1 1.5 2+ RR
RCT 33 patients up to 6 days from symptom onset, showing no significant difference in short-term viral load change with LTX-109.
Important missing comments or errors? Let us know.
viral load, 29.4% higher, relative load 1.29, p = 0.80, treatment 11, control 12, combined.
viral load, 6.4% lower, relative load 0.94, p = 0.96, treatment mean 233.1 (±893.6) n=11, control mean 218.1 (±584.6) n=12, deep nasal swab.
viral load, 93.3% higher, relative load 1.93, p = 0.65, treatment mean 96.19 (±452.8) n=11, control mean 185.9 (±491.6) n=12, anterior nasal swab.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lütken et al., 1 May 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Sweden, preprint, 1 author, trial NCT04854928 (history). Contact: Christian.lutken@pharmaholdings.no, ryvoll@pharmaholdings.no.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2025 Sweden United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR Sweden favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2025 Sweden United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore New Zealand Malawi Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Serbia Syria Sweden favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
This PaperVoxvogananAll
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0